Single Use Bioreactor Market Assessment 2017-2021

Single use bioreactors are witnessing rapid market growth due to increasing applications in production of antibodies, vaccines, recombinant proteins, growth factors and others. Single use bioreactors are not only used in pharmaceutical companies, but also in biotechnology research laboratories and contract manufacturing organizations. Single use bioreactors assure sterile conditions to quickly initiate production. This greatly reduced chances of cross contamination and increases productivity. Shorter turnaround time due to ease of installation, and subverted cleaning and sterilization steps also help in increasing production. Success of monoclonal antibodies as a therapeutic tool in treatment of disease such as cancer and development of vaccines for infectious diseases are other factors driving the single use bioreactor market growth.

The adoption of single use bioreactors is increasing over stainless steel reactors, especially in pharmaceutical industries. Inclination towards biological therapeutic alternatives has escalated applications of bioreactors to a great extent. The single use bioprocessing technology is naive and hence needs more research and guidance in scale up. This has been a hurdle in widespread application of the technology in large scale productions. The adoption is however expected to increasing with growing know how about the production technology. It is also observed that manufacturers are finding it difficult to switch from conventional bioreactors to single use bioreactors. Due to lack of research, it has become a challenge to ascertain production standards for single use reactors. These factors have restricted the single use bioreactor market growth.

Request Free Report Sample@ http://www.sa-brc.com/Global-Single-Use-Bioreactor-Market-Assessment--Forecast-2017-2021/up94

Anticipating rapid market growth, players are engaging in collaboration and acquisitions to stay ahead in the single use bioreactor market. In 2017, Thermo Fisher Scientific, Inc. announced the acquisition of Finesse Solutions. The acquired entity was a long term supplier of measurement and control solutions, and offers data management software. Earlier in 2014 Pal Corporation acquired ATMI Life Sciences to support its single use bioreactor offering. Considering these acquisitions, it is anticipated that newer and better designs would be introduced in the single use bioreactor market in the near future. Rentschler announced that it had increased its single use capacity with two 2,000 lit. and two 1,000 lit. single use bioreactors at its Germany manufacturing facility. Rentschler is a major contract manufacturing organization offering bioprocess development, biomanufacturing and consulting services.

With majority of the bioprocessing facilities and research activities confined in the North America and Europe reaction, the single use bioreactor systems market is mainly accounted by these regions. However with increasing trend for outsourcing production to contract manufacturing organization (CMO), Asia Pacific region would witness faster growth in the near future. Some of the leading players and brands in the make include Hyclone S.U.B. by Thermo Fisher Scientific, CelliGen BLU by Eppendorf, Mobius by Millipore, and XDR by GE Healthcare.

Request For TOC@ http://www.sa-brc.com/Global-Single-Use-Bioreactor-Market-Assessment--Forecast-2017-2021/upcomingdetail94

NOTE: This report is currently under research and will be made available to clients on request.

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
Office No. 14,
Hermes Kunj, Mangaldas Road,
Pune, 411001
India
Phone: +91-02041210872
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.